- ベストアンサー
※ ChatGPTを利用し、要約された質問です(原文:substantial minority)
a substantial minority: improving survival in premenopausal and postmenopausal patients
このQ&Aのポイント
- The Panel considered several situations in which OKBIS might be used with the aim of improving survival, but did not endorse such treatment for this purpose in any group, though a substantial minority felt that premenopausal patients receiving an LHRH agonist plus OKTAM or clearly postmenopausal patients might derive benefit from such treatment.
- Despite not endorsing the use of OKBIS for improving survival, there is a substantial minority who believe that premenopausal patients receiving an LHRH agonist plus OKTAM or clearly postmenopausal patients may benefit from this treatment.
- The use of OKBIS to improve survival was considered by the Panel, but it was not endorsed for any group. However, there is a significant number of individuals who believe that premenopausal patients receiving an LHRH agonist plus OKTAM or clearly postmenopausal patients may derive benefit from this therapy.
- みんなの回答 (3)
- 専門家の回答